/
Immunology
Psoriasis
92
Pipeline Programs↗
172
Active Trials↗
134
Companies Involved↗
Psoriasis is a moderately active landscape with 92 programs across 134 companies. The most active players are Takeda, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD., SFA Therapeutics. 35 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical37
Phase 15
Phase 215
Phase 335
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
67 of 76 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 76 classified programs, each share of the total. Modality classified for 88% of 92 pipeline programs.
Analysis
Trial Status
1,154
clinical trials
Completed832 · 72%
Recruiting81 · 7%
Terminated66 · 6%
Unknown status54 · 5%
Not yet recruiting45 · 4%
Active, not recruiting42 · 4%
Other34 · 3%
Clinical Trials
Trial Activity
1154 trials
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Adult Patients With Moderate to Severe Plaque Psoriasis
Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 3·NCT07724366·400 enrolled
Page 1 of 77
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)